Daré Bioscience Pivots from R&D to Revenue in Women's Health

SAN DIEGO, CA – May 14, 2026 – Daré Bioscience, a company built on the premise of closing critical gaps in women’s healthcare, is poised to make its most significant leap yet: from a research-focused biotech to a commercial enterprise. The company announced today that it expects to record its first-ever direct product revenue in June 2026, a milestone that signals a new era for the firm and a potential turning point for patients in long-underserved markets.

In a call with investors timed to coincide with National Women’s Health Week, President and CEO Sabrina Martucci Johnson framed the moment as the culmination of a long-held conviction. “Daré was built on the conviction that women’s health is an investment-grade category – not a niche, not a nice-to-have, not a pink ribbon in a press release,” she stated. “A category worth building, funding, and holding accountable for delivering to women the healthcare options they deserve.”

This summer, that conviction will be tested as Daré begins dispensing DARE to PLAY™, a first-of-its-kind topical sildenafil cream for female sexual arousal, and launches Flora Sync LF5™, a vaginal probiotic suppository. These launches represent the leading edge of a multi-pronged strategy designed to bring products to market faster while continuing to develop a pipeline of potentially transformative therapies.

The Fast Track: A Dual-Path Gamble

Central to Daré's commercial strategy is an innovative and complex approach it calls the “dual-path strategy.” Instead of waiting years for the traditional, multi-phase FDA approval process to run its course, Daré is leveraging a lesser-known regulatory pathway to get certain products into patients' hands sooner. For DARE to PLAY and its menopause therapy candidate DARE to RECLAIM, the company is partnering with a 503B-registered outsourcing facility.

This pathway, established under the Drug Quality and Security Act, allows specialized facilities to compound drugs in large batches without patient-specific prescriptions, provided they adhere to the FDA's current Good Manufacturing Practice (cGMP) requirements. The advantage is speed. While compounded drugs are not formally FDA-approved and do not undergo the agency's rigorous review for safety and efficacy, the 503B designation provides a higher level of quality control than traditional compounding pharmacies. For Daré, it’s a calculated move to address a significant unmet need for the estimated 20 million U.S. women experiencing challenges with genital arousal, a condition for which no FDA-approved therapy currently exists.

However, this path is not without risk. The FDA maintains that compounded drugs should only be used when an approved product is unavailable or unsuitable, and regulatory scrutiny of 503B facilities is intense. Daré mitigates this risk by simultaneously pursuing the more traditional 505(b)(2) New Drug Application (NDA) pathway for its candidates. This allows the company to use existing data on a drug's active ingredient (like sildenafil) to streamline a future FDA approval, which would confer the gold standard of safety and efficacy validation and unlock broader commercial potential. It’s a strategy that aims for the best of both worlds: near-term access and revenue to address an immediate market gap, followed by long-term validation.

Beyond the Pink Ribbon: A Pipeline for Unmet Needs

While the commercial launches are taking center stage, Daré’s deep pipeline of clinical-stage candidates underscores its broader mission. The company's portfolio targets some of the most significant and often overlooked areas in women's health, from contraception to infectious disease.

One of the most promising candidates is Ovaprene®, a hormone-free, monthly intravaginal contraceptive. This week, Daré announced a second consecutive positive review of interim data from its ongoing Phase 3 trial by an independent Data Safety Monitoring Board (DSMB). The board recommended the study continue without modification, a crucial vote of confidence. With enrollment expected to be completed in 2026, Daré could be on track for a primary endpoint analysis in 2027, potentially bringing the first FDA-approved, hormone-free monthly contraceptive to market.

Another potentially groundbreaking program is DARE-HPV, an investigational therapeutic targeting high-risk human papillomavirus (HPV) infection, the cause of nearly all cervical cancers. An estimated 6 million women in the U.S. contract high-risk HPV annually, yet no FDA-approved drug exists to treat the infection itself. Supported by a $10 million contract from the Advanced Research Projects Agency for Health (ARPA-H), DARE-HPV is advancing into a Phase 2 clinical study this month, representing a major step toward addressing one of the largest unaddressed infectious disease markets affecting women.

The company’s approach is to build families of products, such as the DARE to RESTORE line kicking off with Flora Sync LF5. This vaginal probiotic, backed by a 100-person clinical trial with peer-reviewed results, aims to provide a scientifically validated option in a crowded but often unregulated consumer health space. It will be sold directly to consumers via the company's DARE Health Hub, a telehealth platform designed to connect women efficiently and discreetly with its products.

The Bottom Line: Can Innovation Fund Itself?

For a biotech company, the transition to commercial operations is a moment of truth. Daré reported a net loss of approximately $3.0 million for the first quarter of 2026, an improvement from the $4.4 million loss in the same period last year. As of March 31, 2026, the company held $18.5 million in cash and cash equivalents.

Historically, Daré has masterfully leveraged non-dilutive funding, securing over $75 million in grants from organizations like the NIH and the Bill & Melinda Gates Foundation. This is reflected in its financial reporting, where grant funding is recognized as a “contra-R&D expense,” effectively reducing reported R&D costs. In the first quarter alone, this amounted to $3.5 million, meaning the company’s actual investment in innovation is significantly higher than its net R&D expense of $0.7 million suggests.

Now, product revenue is set to become the third leg of this funding stool. The anticipated revenue from Flora Sync LF5 starting in June and DARE to PLAY in the third quarter is not just a new line on a balance sheet; it is a critical component of the company's future. Johnson emphasized this shift, stating, “Product revenue is not a pivot away from our science. It is an additional source of capital that reinforces it. Grants. Equity financings. And now product revenue. Three legs of a capital structure to enable building without depending on any one source alone.” The coming months will determine if this innovative commercial and financial model can generate the momentum needed to fuel its ambitious scientific pipeline and truly change how women experience healthcare.